Prognosia Breast, an AI-driven mammography tool, receives FDA Breakthrough Device status for improved five-year breast cancer risk prediction.
Key Details
- 1FDA granted Breakthrough Device designation to Prognosia Breast, an AI mammography analysis tool.
- 2Developed by Washington University School of Medicine experts.
- 3Tool predicts five-year breast cancer risk from mammogram findings.
- 4Claims to be twice as accurate as current risk assessment methods.
- 5Aims to inform decisions on supplemental imaging and genetic testing.
Why It Matters
FDA's recognition accelerates the path for advanced AI-enabled risk assessment in breast cancer screening. Improved prediction can enhance early intervention and personalisation, potentially reducing morbidity and mortality.
Source
Health Imaging
Related News
•AuntMinnie
Paul Chang Discusses Foundation Models and Agentic AI at RSNA 2025
Dr. Paul Chang shares his insights on the role of foundation models and agentic AI in radiology at RSNA 2025.
•AuntMinnie
Toronto Study: LLMs Must Cite Sources for Radiology Decision Support
University of Toronto researchers found that large language models (LLMs) such as DeepSeek V3 and GPT-4o offer promising support for radiology decision-making in pancreatic cancer when their recommendations cite guideline sources.
•AuntMinnie
AI Model Using Mammograms Enhances Five-Year Breast Cancer Risk Assessment
A new image-only AI model more accurately predicts five-year breast cancer risk than breast density alone, according to multinational research presented at RSNA 2025.